Development And Evaluation Of A Novel Early Language Assessment Tool To Identify Vulnerable Children Who Would Benefit From Referral To Allied Health Pathways
Funder
National Health and Medical Research Council
Funding Amount
$554,388.00
Summary
Language disorder or delay are best addressed via allied health pathways. However, referral to such services requires a child's carers being able to differentiate typical and atypical development, causing high levels of over- and under-referral. We will develop an early Language and Communication tool that can be used by a child's carers to generate high-quality pre-diagnostic information, enabling appropriate and timely referral, and reducing current burdens on allied health services.
Epigenetic Biomarker Discovery For Cardiovascular Disease Risk Stratification Of Women Following Preeclampsia
Funder
National Health and Medical Research Council
Funding Amount
$1,275,101.00
Summary
Those women whom have suffered from severe complications during pregnancy have an increased risk of developing heart disease. This increased risk may be due to epigenetic changes during pregnancy that alter the expression of specific genes. These epigenetic changes persist after birth and increase heart disease risk for these women. This project seeks to evaluate those epigenetic changes associated with severe pregnancy complications predicting heart disease in a large group of Australian women.
Determining The Molecular Basis Of Therapy Resistance Conferred By Genetic Lesions In The Tumour Protein TP53 In Haematological Malignancies
Funder
National Health and Medical Research Council
Funding Amount
$885,183.00
Summary
Blood cancers that have genetic lesions in a tumour suppressor protein called TP53 respond poorly to therapy. Curing these patients is extremely challenging and new therapeutic strategies are desperately needed. Here, we aim to uncover the molecular mechanisms of drug resistance caused by loss of TP53 function and rationally design new therapies that may be curative. To do this, our team of leading scientists and clinicians will study patient samples and pre-clinical models of blood cancer.